Publication: Lesiones orales producidas por los fármacos inhibidores del mTOR en pacientes en tratamiento de cáncer de mama.
Loading...
Official URL
Full text at PDC
Publication Date
2016
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Description
UCM subjects
Unesco subjects
Keywords
Citation
1 Lippman ME. Principios de Medicina Interna. [Internet]. Volumen 1. Edición 18a. México: McGraw-Hill Interamericana; 13/09/2010. [2012; 4 de Mayo del 2015]. Disponible en: http://harrisonmedicina.mhmedical.com/content.aspx?bookid=865& sectionid =68931874.
2 Bayo-Calero JL. Cáncer de mama: Cuestiones más frecuentes. [internet].Madrid: Entheos; 2007. [consultado el 4 de mayo del 2014]. entheos@editorialentheos.com
3 Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418): 61-70.
4 GLOBOCAN 2012 [Internet]. Lyon, France: IARC; 2012 [2013; Revisado 4 mayo 2014]. Disponible en: http://globocan.iarc.fr
5 FDA [Internet]. Silver Spring, US:Jefferson, E; 1848 (20 de July de 2012; consultado 26 de April de 2015): Disponible en: http://www.fda.gov/newsevents/newsroom/ pressannouncements/ucm312965.htm
6 Miao H, Verkooijen HM, Chia KS, Bouchardy C, Pukkala E, Laronningen S, et al. Incidence and Outcome of Male Breast Cancer: An International Population-Based Study. J Clin Oncol. 2011; 29(33):4381-6.
7 Pérez-García J, Cortés J. Comprender el cáncer de mama (El médico en casa). Barcelona: Amat. 2013.
8 Anderson WF, Chu KC, Chang S, Sherman ME. Comparison of age- specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1128-35.
9 Roja,C. Atlas de patologías Cáncer de Mama. México:Archer Pharma Askepios; 2013.
10 National Cancer Institute [Internet]. USA: SEER Statistic Fact Sheet; 2013. [consultado Mayo,2014].Disponible en:http://seer.cancer.gov/statfacts/html/breast.html.
11 Rosen PP, Groshen S, Saigo PE, et al. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol. 1989; 7: 1239–51.
12 Cortés- Castán J. Comprender el Cancer de Mama. Amat; 2013.
13 Herlofson BB, Norman Pedersen K, Redfors M, Fossa S. Oral Mucosal Side Effects Of Cytotoxic Chemotherapy of Testicular Cáncer. A retrospective study. Eur J Oral Sci. 1997; 105: 526.
14Acevedo, C. Cáncer de Mama: No le des la espalda.Chile: Penguin Random House; 2013.
15 Fatma P, Turkoz FP, Mustafa S, Ibrahim P, Ozge K, Neyran K, Furkan S. Association between common risk factors and molecular subtypes in breast cancer patients. The Breast. 2013; 22: 344-350.
16 Luo J, Margolis KL, Wactawski-Wende J, Horn K, Messina C, Stefanick ML, et al. Association of active and passive smoking with risk of breast cancer among postmenopausal women: a prospective cohort study. BMJ. 2011 Mar 1; 342: 1-8.
17 Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath Jr CW, et al. Collaborative Group on Hormonal Factors in Breast Cancer: Alcohol, tobacco and breast cancer-collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. British Journal of Cancer. 2002; 87:1234-45.
18 Lønning PE, Haynes BP, Straume AH, Dunbier A, Helle H, Knappskog S, et al. Exploring breast cancer estrogen disposition: the basis for endocrine manipulation. Clin Cancer Res. 2011; 17:4948-58.
19 Bergström A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an Avoidable Cause of Cancer in Europe. Int J Cancer. 2001 Feb 1; 91(3):421-30.
20 Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, et al. Body Mass Index, Serum Sex Hormones, and Breast Cancer Risk in Postmenopausal Women. J Natl Cancer Inst. 2003 Aug 20; 95(16): 1218-26.
21 Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG. Hormone-Related Factors and Risk of Breast Cancer in Relation to Estrogen Receptor and Progesterone Receptor Status. Am J Epidemiol. 2000 Apr 1; 151(7):703-14.
22 Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, Breast Cancer Subtypes and Survival in the Carolina Breast Cancer Study. JAMA 2006 Jun 7; 295 (21): 2492-502.
23 Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of Hormone Receptor-Defined Breast Cancer: a Systematic Review of the Literature. Cancer Epidemiology, Biomarkers & Prevention 2004; 13: 1558e68.
24 Haynes BP, Straume AH, Geisler J, et al. Intratumoral Estrogen Disposition in Breast Cancer. Clin Cancer Res. 2010 Mar 15; 16 (6): 1790-801.
25Barnard ME, Boeke CE, Tamimi RM. Established Breast Cancer Risk Factors and Risk of Intrinsic Tumor Subtypes. Review. Biochimic Biophys Acta. 2015 Jun 10; 1856 (1):73–85.
26 Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Research. 2006; 8 (4): R43
27 Folkerd E, Dowsett M. Sex hormones and breast cancer risk and prognosis. The Breast. 2013 Aug; 22 Suppl 2: S38-43.
28 Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst. 2006 Oct 4; 98 (19):1406-15.
29 Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, et al. Association between common risk factors and molecular subtypes in breast cancer patients. Breast. 2013 Jun; 22 (3): 344–350.
30 Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, et al. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012 Jan; 131 (1): 159–167.
31Pollán M, Ascunce N, Ederra M, Murillo A, Erdozáin N, Alés-Martínez J, et al. Mammographic density and risk of breast cancer according to tumor characteristics and mode of detection: a Spanish population-based case–control study. Breast Cancer Res. 2013 Jan 29; 15(1):R9
32 Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J. Natl Cancer Inst. 2011 Feb 2; 103 (3): 250-63.
33Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 2007 Mar; 16 (3): 439-43.
34 Xing P, Li J, Jin F. A case–control study of reproductive factors associated with subtypes of breast cancer in Northeast China. Med Oncol. 2010 Sep; 27 (3): 926-31.
35 Zheng T, Wang J, Chen X, Liu L. Role of microRNA in anticancer drug resistance. Int J Cancer. 2010 Jan 1; 126 (1): 2–10.
36 Li CI, Malone KE, Daling JR, Potter JD, Bernstein L, Marchbanks PA, et al. Timing of menarche and first full-term birth in relation to breast cancer risk. American Journal of Epidemiology. 2008 Jan 15; 167 (2): 230-9.
37 Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Research. 2006; 8 (4):R43.
38 Milne RL, GaudetMM, Spurdle AB, Fasching PA, Couch FJ, Benítez J, et al. Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Research 2010; 12 (6): R110.
39 Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Stefanick ML, Wactawski- Wende J, et al. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomark Prev. 2011; 20 (3):454–463.
40 Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008 May; 109(1): 123–139.
41 Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002; 360: (9328): 187-95.
42 Gaudet MM, Press MF, Haile RW, Lynch CF, Glaser SL, Schildkraut Jet al. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat. 2011; 130 (2): 587–597.
43 Razzaghi H, Troester MA, Gierach GL, Olshan AF, Yankaskas BC, Millikan RC. Association between mammographic density and basal-like and luminal a breast cancer subtypes, Breast Cancer Res. 2013; 15 (5): R76.
44 Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995 Dec;57 (6): 1457–1462.
45 Nelson HD, Huffman LH, Fu R, Harris EL, U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2005 Sep 6; 143 (5): 362–379.
46 Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith HS, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA. 1992 Jun 15; 89(12):5321-5325.
47 Gretarsdottir S, Thorlacius S, Valgardsdottir R, Gudlaugsdottir S, Sigurdsson S, Steinarsdottir M, et al. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res. 1998 Mar 1; 58(5):859-862.
48 Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012; 30(8):777-782.
49 Arnold JM, Choong DY, Thompson ER, Waddell N, Lindeman GJ, Visvader JE, et al. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors. Breast Cancer Res Treat. 2010; Jan 119 (2):491-496.
50 Mir A, Sadegh MH, Ahmadinia Z, Kaboli PJ. PIK3CA rs7640662 (C/G) single nucleotide polymorphism lacks association with breast cancer cases in Persians. Interv Med Appl Sci. 2015 Mar; 7(1):3-8.
51 Chang S, Sharan SK. BRCA1 and MicroRNAs: emerging networks and potential therapeutic targets. Mol Cells. 2012 Nov; 34(5): 425–432.
52 Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007 Apr 10;25 (11): 1329–1333.
53 Tan X, Peng J, Fu Y, An S, Rezaei K, Tabbara S, et al. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin intriple-negative breast cancer. Breast Cancer Res. 2014 Sep 17; 16 (5):435.
54 Kanakkanthara A, Miller JH. MicroRNAs: novel mediators of resistance to microtubule-targeting agents. Cancer Treat Rev. 2013 Apr; 39 (2): 161–170.
55 Shehata M, Van Amerongen R, Zeeman AL, Giraddi RR, Stingl J. The influence of tamoxifen on normal mouse mammary gland homeostasis. Breast Cancer Res. 2014 Jul 24; 16 (4): 411.
56 Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996 May; 13 (1): 123–125.
57 Haraldsson K, Loman N, Zhang QX, Johannsson O, Olsson H, Borg A. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res. 1998 Apr 1; 58 (7):1367–1371.
58 Thorlacius S, Tryggvadottir L, Olafsdottir GH, Jonasson JG, Ogmundsdottir HM, Tulinius H, et al. Linkage to BRCA2 region in hereditary male breast cancer. Lancet. 1995 Aug 26; 346 (8974), 544–545.
59 Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995 Dec 21; 378 (6559): 789–792.
60 Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002 Sep 18; 94 (18): 1365–1372.
61 Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004 Feb 15; 22 (4): 735–742.
62 Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011; 13 (6):224.
63 Siegel, R.; Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014 Jan-Feb; 64 (1): 9–29.
64 Lubinski J, Huzarski T, Byrski T, Lynch HT, Cybulski C, Ghadirian P, et al. The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. Int J Cancer. 2012; 131 (1): 229–234.
65Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, et al. Association between common risk factors and molecular subtypes in breastcancer patients. The Breast. 2013 Jun; 22 (3): 344-350.
66Taylor MA, Garrow JS. Compared with nibbling, neither gorging nor a morning fast affect short-term energy balance in obese patients in a chamber calorimeter. Int J Obes Relat Metab Disord. 2001 Apr; 25(4): 519–28.
67 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr; 61 (2): 69–90.
68Giordano SH, Buzdar AU, Hortobagyi GN. Breast Cancer in men. Ann Intern Med. 2002; 137(8): 678-687.
69 Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer. 1993; 53 (4):538–549.
70 Thomas DB, Jimenez LM, McTieman A, Rosenblatt K, Stalsberg H, Stemhagen A, et al. Breast cancer inmen: risk factors with hormonal implications. Am J Epidemiol. 1991; 135: 734–748.
71 Weiderpass E, Ye W, Adami HO, Vainio H, Trichopoulos D, Nyrén O. Breast cancer risk in male alcoholics in Sweden. Cancer CausesContro. 2001: l12, 661–664.
72 Trivers KF, Jo Lund M, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009; 20 (7): 1071–1082.
73 Inwald EC, Klinkhammer-Schalke M, Hofstadter F, Zeman F, Koller M, Gerstenhauer M, Ortmann O. Ki-67 is a prognostic parameter in breast cancer patients: Results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013; 139(2): 539–552.
74 Han W, Kim SW, Park IA, Kang D, Youn YK, Oh SK, et al. Young age: An independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer. 2004; 4: 82.
75 Broeders M, Moss S, Nyström L, Njor S, Jonsson H, Paap E, et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen. 2012; 19(Suppl 1):14-25.
76Cedolini C, Bertozzi S, Londero AP, Bernardi S, Seriau L, Concina S. Type of Breast Cancer Diagnosis, screening and survival. Clinical Breast Cancer. 2014; 14 (4): 235-40.
77Bodai BI, Tuso P. Breast Cancer Survivorship: A Comprehensive Review of longterm medical issues and lifestyle recommendations. Perm J. 2015; 19 (2):48-79.
78 Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer. 1993; 53: 538–49.
79 Ron E, Ikeda T, Preston DL, Tokuaka S. 2005. Male breast cancer incidence among atomic bomb survivors. J Natl Cancer Inst. 2005; 97 (8): 603–605.
80 Roja, C. Atlas de patologías. México: Archer Pharma. ASKEPIOS. 2013.
81Kaufman SA, Harris EE, Bailey L, Chadha M, Dutton SC, Freedman GM. ACR Appropriateness Criteria Ductal Carcinoma in Situ. Oncology (Williston Park). 2015 Jun; 29(6):446-58, 460-1.
82Evans AJ, Wilson AR, Burrell HC, Ellis IO, Pinter SE, et al. Mammographic features of ductal carcinoma in situ (DCIS) present on previous mammography. Clin Radiol. 1999; 54(10): 644-6.
83 Fadoukhair Z, Zardavas D, Chad MA, Goulioti T, Aftimos P, Piccart M, et al. Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs. Oncogene. 2015 June 29.
84Anderson KN, Schwab RB, Martinez ME. Reproductive risk factors and breast cancer subtypes: a review of the literatura. Breast Cancer Res Treat. 2014; 144 (1): 1-10.
85 Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012 Oct;38 (6): 698– 707.
86 Sweeney C, Bernard PS, Factor RE, Kwan ML, Habel LA, Quesenberry CP, et al. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: Differences by age, race, and tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2014; 23 (5): 714–724.
87 Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE, et al. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol 2009; 169: 1251-9.
88 Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and end Results database. Breast Cancer Res Treat. 2002 Nov; 76 (1): 27-36.
89 Calza S, Hall P, Auer G, Bjohle J, Klaar S, Kronenwett U, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006; 8 (4): R34.
90 National Cancer Institute. Lo que usted necesita saber sobre el cancer de seno™. [Internet]. USA: Publicación de los NIH 13-1556S; Enero de 2013. [consultado 4 mayo 2015]. Disponible en: http://www.cancer.gov/espanol/publicaciones/educacion-parapacientes/ seno.pdf
91 Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, Breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006 Jun 7; 295: 2492-502.
92 Cortese, G. Enfermedades de la glándula mamaria: Manejo integral de la patología benigna y maligna. 1ª edición. Buenos Aires: Editorial Médica Panaamericana. 2014. Páginas 309-371
93 Jordan VC, Lurie RH. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Research and Treatment. 1994; 31: 41-52
94 Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N. Engl J Med. 2003; 348: 2431–2442.
95 Geisler J, King N, Dowsett M, Ottestad L, Lundgren S,Walton P, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer. 1996;74 (8): 1286–1291.
96 Goldhirsch A, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy on Early Breast Cancer 2009. Annals of Oncology. 2009; 20: 1319-1329
97 National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer, Version 2. 2013. [date accessed: 30 may 2015]. Disponible en: www.nccn.com.
98 Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, et al. 1st International consensus guidelines for advanced breast cancer (ACM 1). Breast. 2012; 21: 242–252.
99 Saini KS, Loi S, de Azambuja A, Metzger-Filho O, Saini ML, Ignatiadis M, et al. Targeting the pi3k/Akt/mtor and Raf/mek/erk pathways in the treatment of breast cancer. Cancer Treat Rev 2013:39; 935–46.
100Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.2011; 3: 192–222.
101 Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (pi3k) inhibitors as cancer therapeutics. J Hematol Oncol. 2013; 6:88.
102 Wander SA, Hennessy BT, Slingerland JM. Next-generation mtor inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011; 121:1231–41.
103 Weigelt B and Downward J. Genomic determinants of PI3K pathway inhibitor response in cancer. Review Article [Internet]. August 2012 [Reviewed in May 2015]; 2 (109): 7, 47, 78, 87. https://books.google.es/books?id=pnBEBAAAQBAJ&pg=PA7&dq =mtor&hl=es&sa=X&ei=w8AyVdCHL4KgPaqJgOAH&ved=0CCcQ6AEwAQ#v=onepage&q =mtor&f=true
104 Asociación Española Contra el cáncer (aeec). España. [actualizada el 3 Octubre 2013; 15 Julio 2015]. Available at: https://www.aecc.es/SobreElCancer /CancerPorLocalizacion/ Cancer Mama/Paginas/pronostico.aspx.
105Allemani C, Minicozzi P, Berrino F, Bastiaannet E, Gavin A, Galceran J, et al. Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000-2002. Int J Cancer. 2013; 132 (10): 2404–2412
106 Vainio H, Bianchini F. Breast cancer screening. Lyon, France: IARC Press; 2002.
107Vainio H, Bianchini F, editors. Breast cancer screening. Lyon, France: IARC Press; 2002
108 Hakama M, Coleman MP, Alexe DM, Auvinen A. Cancer screening: evidence and practice in Europe 2008. Eur J Cancer. 2008; 44:1404–13
109 Schopper D, Wolf C. How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer. 2009; 45:1916–23.
110 Gabe R, Duffy SW. Evaluation of service screening mammography in practice: the impact on breast cancer mortality. Ann Oncol. 2005;16 Suppl. 2: 153–62
111 Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: Randomised screening trial. BMJ. 2014; 348: 366.
112 Acevedo-Gadea C, Hatzis C, Chung G, Fishbach N, Lezon-Geyda K, Zelterman D, et al. Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy. Breast Cancer Res Treat 2015;150: 157–167
113 De-Oliveira M, Martins E, Martins F, Wang Q, Sonis S, Demetri G, et al. Clinical presentation and management of mTOR inhibitor associated stomatitis. Oral Oncol. 2011 Oct; 47(10): 998-1003.
114 The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature 2012; 490: 61–70.
115 Kandoth C, McLellan MD, Vandin F, Kai Y, NiuB, Lu C , et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502:333–9.
116 Curtis C, Shah SP, Chin SF, Turashvili G, Rueda O, Dunning M,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486:346–52.
117 Courtney KD, Corcoran RB, Engelman JA. The pi3k pathway as drug target in human cancer. J Clin Oncol. 2010; 28:1075–83.
118 Grabiner BC, Nardi V, Birsoy K, Possemato R, Kuang S,Sumi S, et al. A diverse array of cancer-associated mTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov. 2014; 4:554–63.
119 Chia S, Gandhi S, Joy AA, Edwards S, Gorr M, Hopkins S, et al. Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mTOR pathway for the treatment of breast cáncer. Current Oncology. February 2015; 22 (1):33-48.
120M. Rizell, P. Lindner. Inhibition of mTOR suppresses experimental liver tumours. Anticancer Res. Mar-Apr 2005: 25 (2A): 789–793.
121 Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bech to clinic. Curr Opin Investg Drugs. 2002. 3(2): 295-304
122 Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A,Puc J, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in PTEN+/- mice. Proc Natl Acad Sci. 2001; 98:10320-10325.
123 Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills G. Rapamycin enhances apoptosis and increase sensitivity to cisplatin in vitro. Cancer Res. 1995; 55:1982-1988.
124 Quevedo C, Salinas M, Alcazar A. Regulation of cap-dependent translation by insulin-like growth factor-1 in neuronal cells. Biochem Biophys Res Commun 2002. 291:560-566.
125 Morris RE. Mechanisms of action of new immunosuppressive drugs. Ther Drug Monit. 1995; 17: 564-9.
126 González J, Harris T, Childs G, Prystowsky MB. Rapamycin blocks IL-2 driven T cell cycle progresión while preserving T cell survival. Blood Cells Mol Dis. 2001; 3: 572-85.
127 Bhattacharyya GS, Biswas J, Singh JK, Singh M, Govindbabu K, Ranade AA, et al. Reversal of tamoxifen resistance (hormone resistance) by addition of sirolimus (mTOR inhibitor) in metastatic breast cancer. European Multidisciplinary Cancer Congress Edition Stockholm. Sweden. 2011. Abstract 16LBA
128 Paplomata E, Zelnak A, O´Regan R. Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Res Treat. 2013; 14: 453-462.
129 US Food and Drug Administration [Internet]. USA [4 May 2015]. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ ucm313008.htm.
130Wang-Gillam A, et al. A phase I study of pegylated liposomal doxorubicinand temsirolimus in patients with refractory solid malignancies. Cancer Chemother Pharmacol. 2014; 74:419–426.
131Wang-Gillam A, et al. A phase I study of pegylated liposomal doxorubicinand temsirolimus in patients with refractory solid malignancies. Cancer Chemother Pharmacol (2014) 74:419–426.
132 Garber K. Rapamycin’s resurrection: A new way to target the cancer cell cycle. J Natl Cancer Inst. 2001. 93:1517-1519.
133 Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al. Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients with Cancer. J Clin Oncol. 12 Jun 2004; 22 (12): 2336-2347
134Grünwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M, et al: Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 2002; 62 (21): 6141-6145.
135 Glaxo-SmithKline [Internet]. Tyverb® (lapatinib) prescribing information. USA: [December 2014: accessed July 2015]. www.gsksource.com/gskprm/htdocs/documents/ TYKERB-PI-PIL.PDF
136 Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer. 2004; 91 (8):1420-1424.
137 Cortes J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, et al. Pertuzumab monotherapy after trastuzumab based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2 – positive breast cáncer. J Clin Oncol. 2012. 30(14): 1594-1600.
138Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficay and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER 2 positive breast cáncer (NeoSphere): a randomised multicentre, openlabel, phase 2 trial. Lancet Oncol. 2012. 13(1): 25-32.
139 Higa GM, Abraham J. Lapatinib in the treatment of breast cancer. Expert Rev Anticancer Ther. 2007; 7 (9): 1183-1192.
140 Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol. 2014; 16 (6): 564-575.
141 US Food and Drug Administration. [Accessed in July 2015]. Available at: http//www.fda.gov/Drugs/informationOnDrugs/ ApprovedDrugs/ucm313008.htm.
142 Bjornsti MA, Houghton PJ. The mTOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004; 4:335-48.
143 Los inhibidores de mTOR previenen la mucositis. Diario Médico. Septiembre 2012. Id. vLex: VLEX-396655382. Disponible en: http://vlex.com/vid/396655382. Revisada el 21 octubre 2014
144 Hurvitz S, Dalenc F, Campone M, O'Regan RM, Tjan-Heijnen VC, Gligorov J, Llombart A. A phase 2 study of Everolimus combined with trastuzumab and paclitaxel in patients with HER 2 overexpressing advanced breast cancer that progressed during prior Trastuzumab and taxane therapy. Breast Cancer Res Treat. 2013; 141: 437-446.
145 Baselga J, Campone M, Piccart M, Burris III HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012; 366:520-9.
146 Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 2009; 27: 4536–4541.
147 Afinitor everolimus tablets for oral administration (prescribing information). East Hanover. NI: Novartis Pharmaceuticals Corporation; 2014.
148 Moldawer NP, Wood LS. Management of key adverse events associated with everolimus therapy. Kidney Cancer J. 2010; 8:51-9.
149 Aapro M, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol. 2014; 25:763–773.
150 Kandoth C, McLellan MD, Vandin F, YeK, NiuB, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502:333–9.
151 Kumar V, Sabatini D, Pandey P, Gingras AC, Majumder PK, Kumar M, et al: Regulation of the rapamycin and FKBP-target 1/mammalian target of rapamycin and capdependent initiation of translation by the c-Abl protein-tyrosine kinase. J Biol Chem. 2000; 275: 10779-10787.
152 The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature. 2012; 490: 61–70.
153 Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005; 65 (7):2554-9.
154 Johnston SRD. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res. 2010; 16 (7):1979-87.
155 Pascual J. The use of everolimus in renal-transplant patients. Int J Nephrol Renovasc Dis. 2009; 2:9-21
156 Hoffman R. Hematology: Basic principles and practice. 6th edn. Philadelphia: Elsevier/Saunders; (2013).
157 Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, et al. Stand Up to Cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2–negative metastatic breast cancer. Clin Oncol. 2014; 32:1202–9.
158 Yardley DA. Adverse Event Management of mTOR Inhibitors During Treatment of Hormone Receptore Positive Advanced Breast Cancer: Considerations for Oncologists. Clinical Breast Cancer. 2014; 14 (5): 297-308.
159 Gonzalez A,Akcakanat A, LiuLS, Green MC, Murray JL, Chen H, et al. Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor negative breast cancer. Annals of Oncology. 2014; 25: 1122-1127.
160 García-García C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, et al. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res. 2012; 18: 2603-2612.
161 Qiao L, Liang Y, Mira RR, Yaojuan Lu2, Gu J, ZhengQ. Original Article Mamma lian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2014;7(10):3333-3343
162 Baselga J, Campone M, Piccart M, Howard A, Burris III, Hope S, et al. Everolimus in Postmenopausal Hormone- Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2012; 366:520-9.
163 Kalogirou E, Konstantinos IT, Piperi EP, Sklavounou A. mTOR inhibitor-associated stomatitis (mIAS) in threepatients with cancer treated with everolimus. 2015; 119 (1): e13-e19
164 Boers-Doets CB, Epstein JB, Raber-Durlacher JE, Ouwerkerk J, Logan RM, Brakenhoff JA, et al. Oral adverse events associated with tyrosin kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 2012; 17:135–144.
165 Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010; 116: 210–215.
166 Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, Mita M. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol. 2009; 4:135–142.
167 Sonis ST. A Biological Approach to Mucositis. J Support Oncol. 2004; 2: 21–36
168 National Cancer Institute. Common Terminology Criteria. [Intenet]. May 28, 2009 [Jun 14 2010; Jul 2015] Available in: http://evs.nci.nih.gov/ftp1/ CTCAE /CTCAE _4.03 _2010-06-14_QuickReference_5x7. Pdf
169 Seiler M, Ray-Coquard I, Melichar B, Yardley D, Wang R, Dodion P, et al. Oral Ridaforolimus Plus Trastuzumab for Patients with HER 2 + Trastuzumab refractory metastatic Breast Cancer. Clinical Breast Cancer. 2015; 15 (1): 60-5.
170 Castaneda CA, Cortes–Funes H, Gómez HL, Ciruelos EM,Ciruelos EM. The phosphatidyl inositol 3-kinase/Akt signaling pathway in breast cancer. Cancer Metastasis Rev. 2010; 29:751–9.
171Awada A, Cardoso F, Fontaine C, Dirix L, De Grève J, Sotiriou C, et al. The oral mTOR inhibitor RAD 001 (everolimus in combination with letrozole in patients with advanced breast cáncer: Results of a phase I study with pharmacokinetics. European Journal of cancer. 2008; 44: 84-91.
172 Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012; 149: 274–293.
173 Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010; 116: 4256–4265.
174 Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364: 514–523.
175 Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, et al. Effect of visceral metastases on the efficacy and safety of Everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO 2 study. Eur J Cancer. 2013; 9(12):2621-32.
176 Martins F, de Oliveira MA, Wang Q, Sonis S, Gallottini M, George S, et al. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol. 2013; 49: 293-298.
177 Campone M, Levy V, Bourbouloux E, Berton DR, Bootle D, Dutreix C. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. British Journal of Cancer. 2009; 100, 315 – 321.
178 Jerusalem G, FasoloA, DierasV, CardosoF, Bergh J, VittoriL.Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment. 2011 Jan; 125 (2): 447-55.
179 Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, et al. (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2- negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012; 30(22): 2718–2724.
180Andre F, O’Regan R, Ozguroglu M, Masakazu Toi, Binghe Xu, Guy Jerusalem, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014; 15: 580–91.
181 Piccart-Gebhart MJ, Noguchi S, Pritchard KI, Burris HA, Rugo HS, Gnant M, et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial. J Clin Oncol. 2012; 30(suppl): abstr 559.
182Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Shuchi S. Phase I Study of Neratinib in Combination with Temsirolimus in Patients with Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors. J Clin Oncol. 2013; 32: 68-75.
183 Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER 2 positive advanced breast cancer. N Engl J Med. 2012 Nov 8; 367(19):1783-91.
184 Han HS, Swanton C, Janjigian YY, Sutherland SC, Chandarlapaty S, Lehman R, et al. A phase I study of the AKT inhibitor (MK 2206) with concurrent trastuzumab and lapatinib in patients with HER 2 positive solid tumors. J Clin Oncol. 2011; 29(15) (abstract 3028).
185 Vinayak S, Carlson RW. mTOR inhibitors in the treatment of breast cancer. Oncology. 2013; 27: 38-48.
186 Demetri GD, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor Ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013; 31: 2485-92.
187 Chawla SP, Staddon AP, Baker LH. Phase II study of the mammalian target of rapamycin inhibitor Ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012; 30: 78-84.
188 Seiler M, Ray-CI, Melichar B, Yardley DA, Wang RX, Dodion PF et al. Oral Ridaforolimus Plus Trastuzumab for Patients With HER2þ Trastuzumab-Refractory Metastatic Breast Cancer. Clinical Breast Cancer. 2015; 15 (1): 60-5.
189 Pilotte AP, Hohos MB, Polson KM, et al. Managing stomatitis in patients treated with mammalian target of rapamycin inhibitors. Clin J Oncol Nurs. 2011; 15:E83-9.
190 Divers J. Management of stomatitis associated with mTOR inhibitors in hormone receptor-positive/HER-2 negative advanced breast cancer: clinical experience from a single center. Poster presented at 38th Annual Oncology Nurses’ Society Congress; April 25-28, 2013; Washington, DC.
191 Peterson ME. Management of adverse events in patients with hormone receptorpositive breast cancer treated with everolimus: observations from a phase III clinical trial. Support Care Cancer. 2013; 21:2341–9.
192 Robertson RM. Women and cardiovascular disease: the risks of misperception and the need for action. Circulation. 2001 May 15; 103(19): 2318-20.
193 Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2013 update: a report from the American Heart Association. Circulation. 2013. Jan 1; 127(1):e6-e245.
194 Moy B, Goss PE. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res. 2006; 12:4790– 4793.
195 Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: The effect of CCI 779, an mTOR inhibitor in preclinical models of breast cancer. Endocr Relat Cancer. 2001; 8:249-258.
196 Yue W, Fan P, Wang J, Li Y, Santen RJ. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol. 2007; 106:102–110.
197 Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, et al. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol. 2005; 95:155– 165.
198 Gnant M, Greil R, Hubalek M, Steger G. Everolimus in postmenopausal, Hormone Receptor Positive Advanced Breast Cancer: Summary and Results of an Australian Expert Panel Discussion. Breast Care. 2013; 8: 293-299.
199 NCCN Clinical Practice Guidelines in Oncology. Breast Cancer, Version 2.2012 [Internet]. [Accessed Jul 18, 2015]. Available at: http://www.nccn.org/professionals/ physician_ gls/pdf/breast.pdf>.
200 Gibson L, Lawrence D, Dawson C, Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2009; (4):CD003370.
201 Tabernero J, Rojo F, Burris H, Casado E., Macarulla T., S. Joneset al. A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients with advanced solid tumors. J Clin Oncol. 2005; 23(Suppl. pt 1):193 s [abstract 3007].
202 O’Donnell A, Faivre S, Burris HA, Rea D, Papadimitrakopoulou V, Shand N, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008; 26(10):1588–1595.
203 Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004; 43(2): 83–95.
204 Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S. Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients with Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 2009; 27:4536-4541.
205 Anderson WF, Chu KC, Chang S, Sherman ME. Comparison of age- specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev. 2004; 13, 1128–1135.
206 Boers-Doets CB, Raber-Durlacher JE, Treister NS, Epstein JB, Arends AB, Wiersma DR,et al. Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol. 2013; 9: 1883–1892.
207 Jurge S, Kuffer R, Scully C, Porter S. Mucosal disease series. Number VI. Recurrent aphthous somatitis. Oral Dis Jan 2006; 12 (1):1-21.
208 Scully C, Porter S. Oral mucosal disease: recurrent aphthous stomatitis. BR J Oral Maxillofac Surg Apr 2008; 46 (3); 198-206.
209 Porter S, Scully C. Aphthous ulcers (recurrent). Clin Evid Jun 2005; 13: 1687-94.
210 Femiano F, Buonaiuto C, Gombos F, Lanza A, Cirillo N. Pilot study on recurrent aphthous stomatitis (RAS): a randomised placebo controlled trial for the comparative therapeutic effects of systemic prednisone and systemic montelukast in subjects unresponsive to topical therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Mar 2010; 109 (3): 402-7.
211 Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E. mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant. 2010; 24:149-156.
212 National Cancer Institute. Common terminology criteria for adverse events and common toxicity criteria v3.0 (CTCAE) [Internet]. USA: Published August 9, 2006. [July 1 2015]. Available at: ctep.cancer.gov/protocol Development/electronic applications/ docs/ctcaev3.pdf.
213 White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, et al. Noninfectious pneumonitis after Everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med. 2010; 182 (3): 396–403.
214 Rugo HS, Gnant M, Geberth M et al. Everolimus-related adverse events: safety insights from BOLERO-2. In: Poster presented at: St. Gallen International Breast Cancer Conference; 13–16 March, 2013; St. Gallen, Switzerland. Poster 274. 2013.
215 Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2011; 47: 1287–1298.
216 Tabernero J, Rojo F, Burris H, et al. A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients with advanced solid tumors. J Clin Oncol. 2005; 23(16S):193 s [abstract 3007].
217 Perez A, Rugo HS, Baselga J, et al. Clinical management and resolution of stomatitis in BOLERO-2. Poster presented at 49th Annual Meeting of the American Society of Clinical Oncology; May 31-June 4, 2013; Chicago, IL.
218 Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193–203.
219 Nicolatou-Galitis O, Bafaloukos D, Manolakis G, et al. Oral ulcers in cancer patients who receive mTOR inhibitors: an emerging oral toxicity. Mediterranean Oncol J. 2012; 2:50-56.
220 Ferté C, Paci A, Zizi M, et al. Natural history, management and pharmacokinetics of
everolimus induced oral ulcers: insights into compliance issues. Eur J Cancer 2011; 47: 2249-55.